$LEGN

Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.

Sanders Corazon (Corsee) D. sold 27,370 shares of Legend Biotech Corp (LEGN) at $9.46 ($0.26M total) on 2026-09-29.

Legend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.

Legend Biotech (LEGN) reported $657M in Q2 2026 CARVYKTI sales, up 50% YoY, with global expansion. The company has $965M in cash and appointed Ingrid Zhang as CEO. Challenges include operational bottlenecks and tax uncertainties. LEGN trades at a forward P/E of 27.55.

Legend Biotech Corp. (LEGN) named Ingrid Zhang as CEO, effective September 15. Zhang succeeds Alan Bash, who will return to his role as President of Carvykti. Zhang previously served as Chief Commercial Officer at Novartis. The company aims to advance its pipeline and execute long-term growth strategies. LEGN stock is up 2.70% in pre-market trading at $19.03.

Legend Biotech (LEGN) highlighted its CAR-T therapy CARVYKTI for multiple myeloma, expanding manufacturing, and in vivo CAR-T approaches. The company projects $2.2B revenue and $464.7M earnings by 2029, requiring 20.2% yearly revenue growth. Analysts caution about concentration risks and competition.

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M and net income of $33.2M, reversing a year-earlier loss. The stock has declined 38.5% over 1 year and 68.3% over 3 years, but is up 1.9% year-to-date. Analysts suggest the stock may be undervalued at $21.92, with a fair value estimate of $54.23, citing growth potential in multiple myeloma treatments and expansion opportunities.

Morgan Stanley raised its price target on Legend Biotech (LEGN) to $49 from $48 and maintained an Overweight rating, according to TipRanks. The note highlights continued support from CARVYKTI momentum and valuation, with an unchanged $65 target cited in related coverage.

Legend Biotech Corporation disclosed that certain restricted share units held by executive officers, directors, and a shareholder are under a 60-day lock-up ending 16 Aug 2026, starting 17 Jun 2026. After the lock-up, about 175 million ordinary shares (including ADSs) may enter public sale; total shares outstanding are 386,879,583.